1. Home
  2. CTSO vs HGBL Comparison

CTSO vs HGBL Comparison

Compare CTSO & HGBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTSO
  • HGBL
  • Stock Information
  • Founded
  • CTSO 1997
  • HGBL 1937
  • Country
  • CTSO United States
  • HGBL United States
  • Employees
  • CTSO N/A
  • HGBL N/A
  • Industry
  • CTSO Medical/Dental Instruments
  • HGBL Business Services
  • Sector
  • CTSO Health Care
  • HGBL Consumer Discretionary
  • Exchange
  • CTSO Nasdaq
  • HGBL Nasdaq
  • Market Cap
  • CTSO 65.7M
  • HGBL 74.8M
  • IPO Year
  • CTSO N/A
  • HGBL N/A
  • Fundamental
  • Price
  • CTSO $0.95
  • HGBL $2.17
  • Analyst Decision
  • CTSO Buy
  • HGBL Strong Buy
  • Analyst Count
  • CTSO 2
  • HGBL 1
  • Target Price
  • CTSO $5.50
  • HGBL $4.00
  • AVG Volume (30 Days)
  • CTSO 93.3K
  • HGBL 24.6K
  • Earning Date
  • CTSO 08-07-2025
  • HGBL 08-07-2025
  • Dividend Yield
  • CTSO N/A
  • HGBL N/A
  • EPS Growth
  • CTSO N/A
  • HGBL N/A
  • EPS
  • CTSO N/A
  • HGBL 0.12
  • Revenue
  • CTSO $35,332,238.00
  • HGBL $46,659,000.00
  • Revenue This Year
  • CTSO $11.15
  • HGBL $12.65
  • Revenue Next Year
  • CTSO $21.39
  • HGBL $5.68
  • P/E Ratio
  • CTSO N/A
  • HGBL $18.02
  • Revenue Growth
  • CTSO 15.37
  • HGBL N/A
  • 52 Week Low
  • CTSO $0.71
  • HGBL $1.52
  • 52 Week High
  • CTSO $1.61
  • HGBL $2.43
  • Technical
  • Relative Strength Index (RSI)
  • CTSO 39.94
  • HGBL 52.72
  • Support Level
  • CTSO $0.91
  • HGBL $2.11
  • Resistance Level
  • CTSO $1.06
  • HGBL $2.20
  • Average True Range (ATR)
  • CTSO 0.06
  • HGBL 0.07
  • MACD
  • CTSO -0.01
  • HGBL -0.00
  • Stochastic Oscillator
  • CTSO 13.97
  • HGBL 60.00

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

About HGBL Heritage Global Inc.

Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.

Share on Social Networks: